https://www.dukehealth.org/clinical-trials/directory/pro00119132
TAK-861-3003 | Clinical Trials at Duke
Clinical Trial NCT: NCT07363720 at Duke Health is recruiting patients. View the details of this clinical trial to learn more about participating.
tak 861clinical trials3003duke
https://www.takeda.com/newsroom/newsreleases/2024/takeda-intends-to-rapidly-initiate-the-first-global-phase-3-trials-of-tak-861-an-oral-orexin-agonist-in-narcolepsy-type201-in-first-half-of-fiscal-year-2024/
Takeda to Rapidly Initiate the First Global Phase 3 Trials of TAK-861 in Narcolepsy Type 1
Takeda announced positive topline results from a Phase 2b trial evaluating TAK-861 an oral orexin receptor 2 agonist in patients with narcolepsy type 1
https://www.takeda.com/newsroom/statements/2025/inadvertent-abstract-disclosure-with-attachment/
Statement on Inadvertent Abstract Disclosure for Oveporexton (TAK-861) by World Sleep Congress
An embargoed version of an abstract for our Phase 3 TAK-861-3002 study (RadiantLight) of oveporexton (TAK-861) in narcolepsy type 1, which is slated to be...